News

BioIVT Acquires XenoTech, a Leading Provider of Products and Services for Preclinical Testing of New Drug Candidates

XenoTech specializes in providing ADME-Tox products and research services, in particular drug metabolism and pharmacokinetics (DMPK) and drug-drug interaction (DDI) studies


BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired XenoTech, a provider of products for ADME-Tox in vitro models and contract research services, from Sekisui Chemical, based in Japan. XenoTech specializes in ADME, DMPK and DDI testing of potential drug candidates.

Read more

Macomics Announces the Appointment of Roche Executive, Dr Valérie Méresse Naegelen, to its Clinical Advisory Panel

Macomics Announces the Appointment of Roche Executive, Dr Valérie Méresse Naegelen, to its Clinical Advisory Panel


Edinburgh and Cambridge, UK, 12 September 2022 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to announce that Dr Valérie Méresse Naegelen, Global Head of Translational Sciences Oncology at the Pharma Division of Roche has joined its panel of Clinical Advisors.

Read more

BioIVT Highlights ADME-Tox Research Advances at ISSX/MDO 2022

BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, is highlighting recent ADME-Tox research at the 13th International Meeting of the International Society for the Study of Xenobiotics (ISSX) and 24th International Symposium on Microsomes and Drug Oxidations (MDO). This conference will be held from September 11-14 at the Westin Seattle.

Read more

PhoreMost enters multi-project drug target discovery collaboration with Roche

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes


 

Read more

Macomics to Present at Upcoming Conferences, Q3 2022

Press release


Macomics to Present at Upcoming Conferences, Q3 2022


Edinburgh and Cambridge, UK, 1 September 2022 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to confirm that it will be presenting at a number of upcoming business and scientific conferences, as detailed below.


• Dr Luca Cassetta, co-founder and VP Immunology of Macomics will be attending the 2022 ISEH Annual meeting, Edinburgh, 1-4 September

o Speaking at Q&A session on transition from academia to start up, 2 September

Read more

iPS-Cell Based Cell Therapies for Genetic Skin Disease

AMSBIO has published an interview with Professor Marius Wernig from Stanford University, Pathology Stem Cell Institute that discusses what could be the world’s first widely applicable curative treatment for Epidermolysis Bullosa (EB).


This rare genetic disease causes chronic and incredibly painful skin wounds that often lead to an aggressive form of skin cancer and eventual death.

Read more

The Importance of Destination Locations for Innovation in Life

The next wave of talent “…are looking for destination locations that align with the values and ethos of the company and often the physical structure that’s in to enable innovation is part of what attracts the best people” Tony Jones, One Nucleus.

Read more

One Nucleus August People Pathways

Read August's People Pathways Newsletter


Read more

The Meeting Place – August 2022

Click here to view the August edition of The Meeting Place


Read more

Debunking life science insurance myths

The world of life sciences is complex - add insurance requirements into the mix and it can become a very confusing place to be.


Having appropriate insurance and risk management solutions in place can be crucial for any life science business, whether your seeking initial funding, running clinical trials or taking a product to market.


There are many questions that arise – and myths that surround these topics. Here we share some of the most common myths that have been debunked by CFC Underwriting, a specialist insurance provider to the science and technology sectors.

Read more

Pages